Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

[Case report of introducing MMF and steroids as an immunosuppressive therapy after living-donor liver transplantation for a patient with the diabetic nephropathy].

Kuramitsu S, Iguchi T, Ninomiya M, Yamashita Y, Harimoto N, Ikegami T, Uchiyama H, Yoshizumi T, Soejima Y, Shirabe K, Kawanaka H, Ikeda T, Furuta T, Tamada R, Maehara Y.

Fukuoka Igaku Zasshi. 2014 Mar;105(3):79-83. Japanese.

PMID:
25000660
2.
3.

Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.

Takada Y, Kaido T, Asonuma K, Sakurai H, Kubo S, Kiuchi T, Inomata Y, Isaji S, Tsumura H, Teramukai S, Matsubara Y, Sakabayashi S, Uemoto S.

Liver Transpl. 2013 Aug;19(8):896-906. doi: 10.1002/lt.23679.

4.
5.

Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.

Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.

Transpl Immunol. 2008 Nov;20(1-2):32-42. doi: 10.1016/j.trim.2008.08.005.

PMID:
18773960
6.

Intravenous mycophenolate mofetil with low-dose oral tacrolimus and steroid induction for live donor liver transplantation.

Jain A, Mohanka R, Orloff M, Abt P, Kashyap R, Kelley M, Burlee K, Bozorgzadeh A.

Exp Clin Transplant. 2005 Dec;3(2):361-5.

7.

Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial.

Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD.

Am J Transplant. 2009 Jul;9(7):1607-19. doi: 10.1111/j.1600-6143.2009.02668.x.

8.

Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction.

Jain A, Sharma R, Ryan C, Tsoulfas G, Orloff M, Abt P, Kashyap R, Batzold P, Sauberman L, Safadjou S, Graham M, Bozorgzadeh A.

Liver Transpl. 2008 Feb;14(2):202-9. doi: 10.1002/lt.21348.

9.

Prophylaxis of chronic kidney disease after liver transplantation--experience from west China.

Shao ZY, Yan LN, Wang WT, Li B, Wen TF, Yang JY, Xu MQ, Zhao JC, Wei YG.

World J Gastroenterol. 2012 Mar 7;18(9):991-8. doi: 10.3748/wjg.v18.i9.991.

10.

Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation.

Eckhoff DE, McGuire BM, Frenette LR, Contreras JL, Hudson SL, Bynon JS.

Transplantation. 1998 Jan 27;65(2):180-7.

PMID:
9458011
11.

Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.

Karie-Guigues S, Janus N, Saliba F, Dumortier J, Duvoux C, Calmus Y, Lorho R, Deray G, Launay-Vacher V, Pageaux GP.

Liver Transpl. 2009 Sep;15(9):1083-91. doi: 10.1002/lt.21803.

12.

Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.

Ekberg H, Bernasconi C, Tedesco-Silva H, Vítko S, Hugo C, Demirbas A, Acevedo RR, Grinyó J, Frei U, Vanrenterghem Y, Daloze P, Halloran P.

Am J Transplant. 2009 Aug;9(8):1876-85. doi: 10.1111/j.1600-6143.2009.02726.x.

13.

Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation.

Créput C, Blandin F, Deroure B, Roche B, Saliba F, Charpentier B, Samuel D, Durrbach A.

Liver Transpl. 2007 Jul;13(7):1004-10.

14.

Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant.

Biselli M, Vitale G, Gramenzi A, Riili A, Berardi S, Cammà C, Scuteri A, Morelli MC, Grazi GL, Pinna AD, Andreone P, Bernardi M.

Clin Transplant. 2009 Mar-Apr;23(2):191-8. doi: 10.1111/j.1399-0012.2009.00965.x.

PMID:
19210525
15.
16.

Calcineurin-inhibitor-sparing immunosuppressive protocols.

Bestard O, Cruzado JM, Grinyó JM.

Transplant Proc. 2005 Nov;37(9):3729-32. Review.

PMID:
16386520
17.

Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.

Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, Karrer F, Kam I.

Transplantation. 1997 Dec 27;64(12):1755-60.

PMID:
9422416
18.

Sustained renal response to mycophenolate mofetil and CNI taper promotes survival in liver transplant patients with CNI-related renal dysfunction.

Kornberg A, Küpper B, Thrum K, Krause B, Büchler P, Kornberg J, Sappler A, Altendorf-Hofmann A, Wilberg J, Friess H.

Dig Dis Sci. 2011 Jan;56(1):244-51. doi: 10.1007/s10620-010-1386-z.

PMID:
20824504
19.

Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation.

Hao JC, Wang WT, Yan LN, Li B, Wen TF, Yang JY, Xu MQ, Zhao JC, Wei YG.

World J Gastroenterol. 2014 Aug 28;20(32):11356-62. doi: 10.3748/wjg.v20.i32.11356.

20.

Calcineurin inhibitor minimization protocols in liver transplantation.

Farkas SA, Schnitzbauer AA, Kirchner G, Obed A, Banas B, Schlitt HJ.

Transpl Int. 2009 Jan;22(1):49-60. doi: 10.1111/j.1432-2277.2008.00796.x. Review.

Items per page

Supplemental Content

Support Center